Nuvation Bio Inc. (NUVB)
| Market Cap | 1.59B +108.7% |
| Revenue (ttm) | 143.05M +1,205.5% |
| Net Income | -145.99M |
| EPS | -0.42 |
| Shares Out | 348.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 613,968 |
| Open | 4.610 |
| Previous Close | 4.720 |
| Day's Range | 4.565 - 4.680 |
| 52-Week Range | 1.570 - 9.750 |
| Beta | 1.52 |
| Analysts | Strong Buy |
| Price Target | 12.25 (+167.47%) |
| Earnings Date | May 4, 2026 |
About NUVB
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company’s lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headqua... [Read more]
Financial Performance
In 2025, Nuvation Bio's revenue was $62.90 million, an increase of 698.96% compared to the previous year's $7.87 million. Losses were -$204.63 million, -63.97% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for NUVB stock is "Strong Buy." The 12-month stock price target is $12.25, which is an increase of 167.47% from the latest price.
News
Nuvation Bio collaborating with Thermo Fisher to manufacture Ibtrozi in NSCLC
Nuvation Bio (NUVB) announced the completion of process tech transfer and product introduction to Thermo Fisher (TMO) for Ibtrozi – taletrectinib – to treat advanced or metastatic ROS1-positive non-sm...
Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer
Thermo Fisher Scientific, the world leader in serving science, will now manufacture drug product for Nuvation Bio in the United States Move by Nuvation Bio further ensures critical drug supply for pat...
Nuvation Bio Transcript: Bank of America Global Healthcare Conference 2026
ZUSDURI's launch is exceeding expectations with rapid revenue growth, strong community adoption, and durable clinical benefit. Pipeline assets are advancing, including next-gen mitomycin and an oncolytic virus, supporting ambitions to expand beyond urothelial cancers.
Nuvation Bio: FDA accepts sNDA with updated data for IBTROZI
Nuvation Bio (NUVB) announced that the U.S. FDA has accepted a supplemental New Drug Application with updated data for IBTROZI in both TKI-naive and TKI-pretreated advanced ROS1-positive non-small cel...
Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer
Application includes updated TRUST-I TKI-naïve median duration of response (mDOR) and median progression-free survival (mPFS) of more than 4 years, as well as TRUST-II TKI-pretreated mDOR of nearly 20...
Nuvation Bio to Participate in Upcoming Investor Conferences
NEW YORK, May 5, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung...
Nuvation Bio Earnings Call Transcript: Q1 2026
Strong Q1 2026 results driven by Ibtrozi's expanding first-line use, robust revenue growth, and broad adoption across U.S. and international markets. Safusidenib program advanced with global rights secured and pivotal trial expansion.
Nuvation Bio reports Q1 EPS 1c, consensus 5c
Reports Q1 revenue $83.23M, consensus $62.34M. “We are pleased with IBTROZI’s ongoing launch trends in the first quarter of 2026, as we continue to deepen its adoption across lines of…
Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Achieved $18.5 million in first quarter of 2026 net product revenues for IBTROZI ® (taletrectinib); majority of the approximately 200 patients started on IBTROZI in the first quarter of 2026 were TKI-...
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers
Guidelines include the next-generation targeted therapy as a systemic option for patients with ROS1-positive non-small cell lung cancer with brain metastases NEW YORK, April 27, 2026 /PRNewswire/ -- N...
Nuvation Bio reports results from TRUST-I and TRUST-II trials for IBTROZI
Nuvation Bio (NUVB) announced results from a pooled analysis of long-term follow-up data from the pivotal TRUST-I and TRUST-II trials for IBTROZI, or taletrectinib, in patients with advanced ROS1-posi...
Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026
Analysis of longer-term pooled data from TRUST-I and TRUST-II demonstrated nearly 50 months median duration of response and 46.1 months median progression-free survival in TKI-naïve patients IBTROZI a...
Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026
NEW YORK, April 20, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host...
Nuvation Bio amends license agreement for safusidenib with Daiichi Sankyo
Nuvation Bio (NUVB) announced the company has amended its existing exclusive license agreement for safusidenib with Daiichi Sankyo to include Japan rights, effectively securing exclusive global develo...
Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo
With acquisition of Japan rights, Nuvation Bio now has global development and commercialization rights for safusidenib Agreement provides Nuvation Bio ownership of global clinical development program,...
Nuvation Bio and Eisai’s MAA for taletrectinib in NSLC accepted in Europe
Nuvation Bio (NUVB) and Eisai Co. (ESAIY) announced that the European Medicines Agency, or EMA, has validated the Marketing Authorisation Application, or MAA, for taletrectinib for the treatment of ad...
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
The Marketing Authorisation Application (MAA) has been validated and accepted for full approval consideration with a standard review timeline Additional filings are planned for the U.K., Canada and ot...
Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026
Clinical data demonstrate IBTROZI's unprecedented durability in TKI-naïve advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC), with median Duration of Response (DOR) now increased to 50 ...
Nuvation Bio Transcript: The Citizens Life Sciences Conference 2026
IBTROZI's launch has outpaced competitors with strong first-line growth, robust efficacy, and favorable safety, supported by evolving guidelines and efficient commercial execution. Pipeline assets, including safusidenib, show promising data and expansion into new indications.
Nuvation Bio falls -25.3%
Nuvation Bio (NUVB) is down -25.3%, or -$1.48 to $4.36.
Nuvation Bio Transcript: TD Cowen 46th Annual Health Care Conference
Patient starts and revenue are growing, with first-line share increasing and strong drug durability supporting long-term outlook. International expansion is progressing, and pipeline trials target significant unmet needs in glioma. Cash reserves are robust, enabling further business development.
Nuvation Bio falls -25.3%
Nuvation Bio (NUVB) is down -25.3%, or -$1.48 to $4.36.
Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Nuvation Bio Inc. (NYSE: NUVB). The investigation focuses on whether Nuva...
Nuvation Bio falls -25.6%
Nuvation Bio (NUVB) is down -25.6%, or -$1.50 to $4.34.
Nuvation Bio falls -26.1%
Nuvation Bio (NUVB) is down -26.1%, or -$1.52 to $4.32.